OX1 receptor antagonist C4X_3256 demonstrates efficacy in nicotine dependence rat model Nov. 15, 2017
FDA committee recommends approval of Braeburn Pharmaceuticals' CAM-2038 for opioid use disorder Nov. 2, 2017
NIDA grant supports Camino Pharma's development of compounds for substance use disorders Sep. 29, 2017
RSS